Dramatic advances in diagnosis, treatment and surgery are improving—and saving—many lives

What You Need to Know

  • 89 percent of women with breast cancer survive for five years or more, thanks to better detection and more personalized therapies
  • Experts now divide breast cancer into three subtypes, and are developing treatments for each type
  • More than half of breast cancer sufferers can skip chemo and radiation and opt for medications with fewer side effects, like tamoxifen

Women Image - Masterfile

In the past, breast cancer treatment was "one-size-fits-all" and the therapies were few. More women than necessary underwent radical surgery, radiation and chemotherapy and experienced such side effects as nausea, hair loss, fatigue and chronic arm swelling. "Today we have more sophisticated diagnostic techniques and treatment options," says Wendy Chen, M.D., M.P.H., an oncologist at the Dana-Farber Cancer Institute in Boston. "If you’re diagnosed with breast cancer, you’ll get the treatment that fits you." Here, see how far we’ve come.

The Latest in Breast Cancer Diagnosis

THEN

Mammography and biopsies

NOW

Sophisticated biopsy techniques, digital mammography and genetic tests identify tumors as one of three types (this helps determine your menu of treatments):

  • ER-positive and/or PR-positive Tumors with receptors that attach to hormones estrogen and/or progesterone.
  • HER2-positive Tumors that contain too much of a growth-promoting protein called HER-2.
  • Triple-negative Tumors that test negative for hormone receptors and HER-2.

The Future

Research seeks to identify the characteristics and behavior of genes associated with breast cancer, pinpoint each cancer’s unique "fingerprint" and personalize treatment further. "We are also trying to identify markers in the blood that can tell us whether cancer has traveled beyond the breast," says Vered Stearns, M.D., associate professor of oncology and co-director, Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore.

Breast Cancer Treatment Advances

THEN

Overkill in use of radiation and chemotherapy, both of which have potentially serious side effects.

NOW

Identification of three breast cancer subtypes and the advent of medications for each subtype have shown chemotherapy is not always indicated. More than half of U.S. women with breast cancer have estrogen-receptor-positive tumors that have not spread to the lymph nodes.

These can often be treated with oral hormonal therapies, such as tamoxifen (Nolvadex and others). Women with HER-2 positive tumors can be treated with trastuzumab (Herceptin). The side effects of these newer drugs are generally more easily tolerated than those of chemotherapy.

For women who can benefit from chemotherapy, there are many more options along with new add-on medications that can help prevent side effects such as nausea and vomiting.

On the radiation front, some women with early-stage cancers may be candidates for a three-week course instead of the standard six-week course. Women with stage 1 or stage 2 tumors no bigger than three centimeters may qualify for a targeted type of radiation, MammoSite. This pinpoints the area in which cancer is most likely to recur while sparing surrounding tissue.

The Future

Increasingly targeted treatments will continue to reduce the number of women who require radiation and chemotherapy. A major goal is to find a cure for breast cancer that has spread (metastatic cancer).

Avoid Chemo? New Gene Test May Say Yes

When deciding whether to prescribe chemotherapy after breast cancer surgery, doctors have traditionally relied on the size and grade of a woman’s breast tumor, along with the cancer status of her lymph nodes. For the past couple of years, women with early-stage ER-positive breast cancer have had another test at their disposal. The Oncotype DX test, which examines the activity level of 21 genes within tumor cells, can predict how aggressive a tumor is and how likely cancer is to recur. This helps doctors identify women who may not benefit from chemotherapy.

Strides in Breast Cancer Surgery

THEN

Removal of the entire breast (mastectomy) was the gold standard. In addition, surgeons took up to 30 lymph nodes from the armpit if even one or two tested positive.

NOW

Lumpectomy—in which only the tumor and the area around it are removed—has replaced the need for mastectomy in at least 70 percent of women. At the same time, more women with breast cancer or at high risk for it are electing to have mastectomies, influenced largely by new reconstructive techniques that reduce scarring, notes Patricia Dawson, M.D., Ph.D., a breast cancer surgeon at Seattle’s Swedish Cancer Institute.

A groundbreaking study in the February 2011 issue of the Journal of the American Medical Association (JAMA) has dramatically altered practice standards regarding lymph-node removal as well. The study showed that for women whose cancers meet certain criteria (less than five centimeters and with no more than three nodes containing tumor cells), leaving the axillary, or armpit, nodes in place has no effect on long-term survival. This means some 92 percent of women with early-stage breast cancers that have spread to a nearby lymph node can avoid complications commonly caused by extensive lymph node removal.

Less Lymphedema?

When doctors take out numerous lymph nodes to halt cancer’s spread, it can compromise your lymphatic system, which filters harmful fluids from your tissues. Fluids can build up under your skin, causing uncomfortable, unsightly arm swelling called lymphedema. This may require extensive physical therapy. Last February’s JAMA study may reduce the rates of this common post- surgical problem.

The Future

Doctors continue to strive to make breast surgery even less visually damaging. Nipple-sparing mastectomy, which removes the breast but allows a woman to keep her nipple and areola, will likely become more widely available in carefully selected patients, as more surgeons perfect these techniques.

From our sister publication, Remedy’s Healthy Living, Fall 2011

Publication Review By: the Editorial Staff at Healthcommunities.com

Published: 27 Jul 2011

Last Modified: 03 Sep 2015